: Management projects generating positive free cash flow in 2026 , driven by reduced operating expenses and an debt-free balance sheet .
: Upgrades by mathematical models highlight that short-term earnings estimates are improving faster than the market expects . ⚠️ The Case for Selling AMRN Google's Finance Data
: While U.S. revenues have shrunk due to generics, the company's flagship drug, Vascepa, continues to roll out in international markets .
: Amarin is transitioning from a growth story to a cost-disciplined turnaround play after aggressive corporate restructuring .